×
About 965 results

ALLMedicine™ Anaplastic Thyroid Cancer Center

Research & Reviews  331 results

Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer...
https://doi.org/10.1016/j.annonc.2021.12.014
Annals of Oncology : Official Journal of the European Soc... Subbiah V, Kreitman RJ et. al.

Jan 14th, 2022 - Combined therapy with dabrafenib plus trametinib was approved in several countries for treatment of BRAF V600E-mutant anaplastic thyroid cancer (ATC) based on an earlier interim analysis of 23 response-evaluable patients in the ATC cohort of the p...

Combination of Lenvatinib and Pembrolizumab as Salvage Treatment for Paucicellular Vari...
https://doi.org/10.3390/curroncol28060450
Current Oncology (Toronto, Ont.); Luongo C, Porcelli T et. al.

Dec 24th, 2021 - Anaplastic thyroid cancer (ATC) is a rare but aggressive thyroid cancer, responsible for about 50% of all thyroid cancer-related deaths. During the last two decades, the development of a multimodal personalized approach resulted in an increased su...

Metastatic Clear Renal-Cell Carcinoma Mimicking Anaplastic Thyroid Cancer: A Case Report.
https://doi.org/10.1177/01455613211065512
Ear, Nose, & Throat Journal; Silver JA, Roy CF et. al.

Dec 15th, 2021 - Metastatic renal cell carcinoma to the thyroid is a rare yet aggressive histopathologic diagnosis, which may often be omitted from the initial clinical differential. This is in part due to the long latency period between the initial renal primary ...

Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeu...
https://doi.org/10.1007/978-3-030-83282-7_2 10.1016/S0092-8674(00)81683-9 10.1016/j.cell.2011.02.013 10.1111/j.1600-065X.1971.tb00461.x 10.1111/j.1600-065X.1976.tb00189.x 10.1038/nm.3909 10.1038/nri3920 10.1038/ni.3341 10.3389/fimmu.2015.00486 10.1158/0008-5472.CAN-07-0912 10.1016/j.ccr.2011.02.005 10.1016/j.ccell.2017.07.001 10.1038/s41577-019-0127-6 10.1016/j.cell.2008.09.016 10.20900/immunometab20190015 10.3390/cancers11060750 10.3389/fonc.2019.01143 10.1242/dmm.034272 10.1007/s00262-018-2195-z 10.3389/fimmu.2019.00925 10.1158/1078-0432.CCR-14-0291 10.1126/science.1198687 10.1038/sj.emboj.7600019 10.1016/j.intimp.2018.09.016 10.1038/nri3442 10.3892/ol.2017.5681 10.3389/fcell.2020.00766 10.3389/fimmu.2019.00147 10.1101/cshperspect.a006536 10.3390/ijms19051272 10.1186/s12943-017-0597-8 10.1016/j.semcancer.2019.06.003 10.1038/nrc.2016.73 10.1186/s12967-018-1536-1 10.3390/ijms19051532 10.3389/fimmu.2019.01835 10.1097/PPO.0000000000000118 10.1098/rsob.190297 10.3389/fonc.2020.00569 10.3389/fonc.2020.00722 10.1016/j.canlet.2019.07.010 10.1016/j.semcancer.2014.02.007 10.1038/s41423-020-0505-9 10.1016/j.immuni.2019.06.025 10.3390/ijms21155521 10.1016/j.cell.2004.07.011 10.1016/j.ccr.2013.03.004 10.1172/JCI39104 10.1038/nrm1835 10.1084/jem.20051848 10.1016/j.ccr.2012.04.024 10.1158/2326-6066.CIR-15-0241 10.1242/jcs.237453 10.1093/carcin/bgu060 10.3803/EnM.2013.28.3.192 10.1677/ERC-08-0036 10.1371/journal.pone.0022567 10.1002/path.1731 10.3892/mco.2013.170 10.1111/cen.12586 10.3892/ol.2019.9940 10.1073/pnas.0509182102 10.1097/MD.0000000000006472 10.3389/fonc.2019.01270 10.1038/s41416-019-0540-4 10.1158/10780432 10.1530/ERC-16-0421 10.1126/science.aar4060 10.1038/nrm3758 10.1007/s10911-010-9178-9 10.1074/jbc.M113.528026 10.1371/journal.pone.0036132 10.1038/srep09489 10.1016/j.stemcr.2014.03.008 10.1038/sj.bjc.6605530 10.1016/j.cell.2004.06.006 10.1016/j.tcb.2015.07.012 10.1101/gad.225334.113 10.1242/jcs.02552 10.1074/jbc.M005912200 10.1016/j.ccr.2009.03.016 10.1038/sj.onc.1210546 10.1016/j.canlet.2013.02.033 10.1186/s12902-019-0351-x 10.1158/0008-5472.CAN-05-2514 10.4049/JIMMUNOL.172.7.4100 10.1158/1078-0432.CCR-11-1595 10.1155/2013/857519 10.1186/s40425-018-0378-y 10.1097/CMR.0000000000000355 10.1210/jc.2018-01167 10.1016/j.immuni.2016.04.019 10.1016/j.prp.2019.04.002 10.3390/ijms20092198 10.1189/jlb.0809590 10.1172/JCI120966 10.1158/0008-5472.CAN-17-1653 10.1002/mc.22418 10.1158/1535-7163.MCT-19-0183
Advances in Experimental Medicine and Biology; Chakraborty S, Carnazza M et. al.

Dec 11th, 2021 - Thyroid cancer incidence is increasing at an alarming rate, almost tripling every decade. About 44,280 new cases of thyroid cancer (12,150 in men and 32,130 in women) are estimated to be diagnosed in 2021, with an estimated death toll of around 22...

Inflammatory Components of the Thyroid Cancer Microenvironment: An Avenue for Identific...
https://doi.org/10.1007/978-3-030-83282-7_1 10.1038/nri855
Advances in Experimental Medicine and Biology; Jarboe T, Tuli NY et. al.

Dec 11th, 2021 - The incidence of thyroid cancer in the United States is on the rise with an appreciably high disease recurrence rate of 20-30%. Anaplastic thyroid cancer (ATC), although rare in occurrence, is an aggressive form of cancer with limited treatment op...

see more →

Guidelines  2 results

2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349723
Thyroid : Official Journal of the American Thyroid Associ... Bible KC, Kebebew E et. al.

Mar 18th, 2021 - Background: Anaplastic thyroid cancer (ATC) is a rare but highly lethal form of thyroid cancer. Since the guidelines for the management of ATC by the American Thyroid Association were first published in 2012, significant clinical and scientific ad...

Anaplastic Thyroid Carcinoma, Version 2.2015.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986600
Journal of the National Comprehensive Cancer Network : JN... Haddad RI, Lydiatt WM et. al.

Sep 12th, 2015 - This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Thyroid Carcinoma focuses on anaplastic carcinoma because substantial changes were made to the systemic therapy recommendations for the 2015 update. Dosage...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  11 results

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
https://clinicaltrials.gov/ct2/show/NCT03449108

Nov 19th, 2021 - PRIMARY OBJECTIVE: I. To evaluate efficacy using objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 in each cohort. SECONDARY OBJECTIVES: I. Determine the disease control rate (DCR) within and ...

Assessment of CA 19-9 in Patients' With Thyroid Malignancies
https://clinicaltrials.gov/ct2/show/NCT05124938

Nov 18th, 2021 - Thyroid cancer is a rare disease that represents approximately 3.8% of all new cancer cases.Incidence of thyroid cancer in north Africa about 2.8% of all new cancer cases with mortality rate about 0.73%.Thyroid malignancies are classified into dif...

Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
https://clinicaltrials.gov/ct2/show/NCT01236547

Oct 21st, 2021 - PRIMARY OBJECTIVES: I. To evaluate the safety of IMRT, paclitaxel, and pazopanib (pazopanib hydrochloride) suspension. (Run-in component) II. To evaluate and compare overall survival at 1 year from study registration. (Phase II component) SECONDAR...

Multiple Target Kinase Inhibitor and Anti-Programmed Death-1 Antibody in Patients With Advanced Thyroid Cancer
https://clinicaltrials.gov/ct2/show/NCT04521348

May 19th, 2021 - We will recruit four types of advanced thyroid cancer patients. Arm A will enroll the radioactive Iodine-refractory differentiated thyroid cancer(RAIR-DTC). Arm B will recruit the advanced medullary thyroid cancer(MTC). Arm C will include the adva...

Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer
https://clinicaltrials.gov/ct2/show/NCT04731740

May 17th, 2021 - Primary endpoint Objective Response Ratio (ORR) [Time frame: prior to study completion, average 3 years] Evaluate the effectiveness of a combination of a PD-1 inhibitor (pembrolizumab) with a multikinase inhibitor (lenvatinib) using an objective r...

see more →

News  41 results

Lenvatinib/Pembro Combo for Advanced Anaplastic Thyroid Cancer
https://www.medscape.com/viewarticle/960492

Oct 8th, 2021 - In patients with metastatic anaplastic thyroid cancer who have progressed on chemotherapy — who have a poor prognosis —a new combination of nonchemotherapy drugs shows promise. The combination of the multikinase inhibitor lenvatinib with the immun...

NTRK- and RET-Targeted Agents Reshape Solid Tumor Landscape
https://www.onclive.com/view/ntrk-and-ret-targeted-agents-reshape-solid-tumor-landscape

Aug 5th, 2021 - Understanding the oncogenic drivers behind a cancer is taking on increasing importance as more effective agents targeting specific gene aberrations continue to emerge. Two classes of precision agents that have recently had drugs come onto the mark...

Innovation Fuels Breakthroughs for Rare Cancers
https://www.onclive.com/view/innovation-fuels-breakthroughs-for-rare-cancers

Jun 2nd, 2021 - Although there are only approximately 10,000 people in the United States living with von Hippel-Lindau (VHL) syndrome, nearly 3 dozen cancer institutes and hospitals throughout the nation have joined a network of specialized clinical centers for d...

Larotrectinib Achieves High Marks in NTRK-Mutant Thyroid Cancer
https://www.onclive.com/view/larotrectinib-achieves-high-marks-in-ntrk-mutant-thyroid-cancer

May 26th, 2021 - Larotrectinib (Vitrakvi) has proved to be highly active in patients with thyroid cancer with NTRK gene fusions, exhibiting rapid and durable disease control, according to Maria E. Cabanillas, MD. Cabanillas, professor of clinical research in the ...

Actionable Driver Mutations in Medullary Thyroid Cancer
https://www.onclive.com/view/actionable-driver-mutations-in-medullary-thyroid-cancer

Apr 2nd, 2021 - Lori J. Wirth, MD: For medullary thyroid cancer, all patients need to have molecular testing done. Now we’re looking for 2 different things in molecular testing. It’s complicated, though not really. As I mentioned, medullary thyroid cancer [MTC] c...

see more →